CD34 and sickle cell disease: The first CRISPR clinical trial in the US was initiated in 2018 and involved use of autologous CD34+ HSPCs modified with CRISPR-Cas9 to upregulate the expression of fetal hemoglobin as a treatment for sickle cell disease and β-thalassemia (NCT03655678).